NCT07126158 2026-04-15
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
Phase 2 Recruiting
Clinical Trials
18 trialsNCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06495125 2026-04-06
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Emory University
Phase 2 Recruiting
NCT06369259 2026-04-01
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06007924 2026-03-27
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04331041 2026-03-25
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT05787561 2026-03-12
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03727880 2026-02-04
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT06394804 2026-02-03
CHAMELEON
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06682572 2025-12-17
RAMP201J
Verastem, Inc.
Phase 2 Active not recruiting
NCT06487221 2025-11-04
Avutometinib and Defactinib in Diffuse Gastric Cancer
Columbia University
Phase 2 Recruiting
NCT05512208 2025-10-22
DURAFAK
University of Oklahoma
Phase 2 Recruiting
NCT04720417 2025-07-15
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
Thomas Jefferson University
Phase 2 Terminated
NCT04625270 2025-01-29
RAMP 201
Verastem, Inc.
Phase 2 Active not recruiting
NCT02004028 2024-02-20
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
Phase 2 Terminated
NCT04620330 2024-01-12
RAMP202
Verastem, Inc.
Phase 2 Completed
NCT01951690 2017-04-13
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Verastem, Inc.
Phase 2 Completed
NCT01870609 2017-01-30
COMMAND
Verastem, Inc.
Phase 2 Terminated